Detection Rate Stratified by PSA Level and Other Parameters on a Per-Patient Basis
| Stratification | n | No. of PET-positive results (%) | χ2 P value |
|---|---|---|---|
| All patients | 532 | 423 (80) | |
| PSA (ng/mL) | 0.005 | ||
| <0.5 | 166 | 96 (58) | |
| 0.5 – <1.0 | 104 | 90 (87) | |
| 1.0 – <2.0 | 102 | 87 (85) | |
| 2.0 – <5.0 | 86 | 80 (93) | |
| ≥5.0 | 74 | 70 (95) | |
| PSA doubling time (mo) | 0.449 | ||
| <6.8 | 59 | 49 (83) | |
| ≥6.8 | 62 | 44 (71) | |
| Not available | 411 | 330 (80) | |
| PSA nadir after prostatectomy (ng/mL) | <0.001 | ||
| <0.1 | 135 | 103 (76) | |
| ≥0.1 | 86 | 72 (84) | |
| Not available | 311 | 248 (80) | |
| Time from initial therapy to PSMA PET (y) | 0.785 | ||
| <4.7 | 264 | 207 (78) | |
| ≥4.7 | 267 | 215 (81) | |
| Not available | 1 | 1 (100) | |
| Gleason score | 0.483 | ||
| ≤7 | 155 | 119 (77) | |
| ≥8 | 116 | 98 (84) | |
| Not available | 261 | 206 (79) | |
| Primary T stage | 0.555 | ||
| ≤T2 | 152 | 116 (76) | |
| ≥T3 | 288 | 235 (82) | |
| Not available | 92 | 72 (78) |